Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Gsk | History Defined

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

MarketBeat

FDA issues new kidney warning for weight loss pill

Alli was the first over-the-counter weight loss pill approved by the U.S. Food and Drug Administration

The Independent UK

Nuvalent Stock Hits All-Time High Following GSK's Buyout Offer

Nuvalent shares soar as GSK announces a $10.6 billion buyout deal. But is it too late already to invest in NUVL stock?

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

More swings for AI stocks drag Wall Street back on the roller coaster

More sudden reversals for high-flying artificial-intelligence stocks sent Wall Street reeling

AAP

Another sell-off for AI stocks sends Wall Street reeling

Another sell-off for artificial-intelligence stocks whipsawed Wall Street

AAP

Why is the US stock market crashing today? S&P 500 erases all gains and wipes out $1.3 trillion in 2 hours as Nasdaq and Dow turn sharply lower - Tech stocks and chip sector collapse

The US stock market crash today caught many investors off guard. Early gains quickly vanished as the S&P 500 erased more than $1.3 trillion in market value within just two hours. What began as a relief rally suddenly turned into a broad sell-off that dragged down the Nasdaq, Nvidia, Apple,…

The Economic Times

Another sell-off for AI stocks drags Wall Street sharply lower

Another sell-off for artificial-intelligence stocks is dragging Wall Street sharply lower

AAP

Read news from The Economist, FT, and more,
with one subscription

Wall Street falls sharply as AI stocks resume their sell-off

Artificial-intelligence stocks are resuming their sell-off, and the former superstars that had led the market to records are dragging Wall Street down with them

AAP

FTSE 100 down as Asia-focused financials struggle

Oil prices also fell after US President Donald Trump said negotiations over a peace deal to end the Middle East war were in their final stages.

Evening Standard

Wall Street drops as AI stocks slide sharply again

Artificial-intelligence stocks are tumbling again, and the former superstars that had led the market to records are dragging Wall Street along with them

AAP

Wall Street yo-yos as AI stocks swing from gains to losses

The U.S. stock market is yo-yoing as artificial-intelligence stocks keep swinging following their sudden and sharp losses from last week

AAP

Wall Street ticks higher as AI stocks recover more losses and oil prices ease

The U.S. stock market is ticking higher as artificial-intelligence stocks regain more of their sudden and sharp losses from last week, while oil prices ease

AAP

Global Markets: European shares edge higher with banks in the lead; the Middle East in focus

European markets saw a rise on Tuesday. Banking stocks led the gains, with Italian lenders drawing attention. Tech stocks stabilized after recent volatility. GSK shares fell following a deal to acquire Nuvalent. UBS saw an increase on reports of potential capital requirement adjustments. Investors monitored developments in the Middle East…

The Economic Times

GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm

Nuvalent’s late-stage lung cancer treatments zidesamtinib and neladalkib are expected to launch later this year

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

GSK to buy US lung cancer drug specialist Nuvalent for £8bn

The acquisition is thought to be GSK’s biggest deal in more than a decade.

AAP

Experimental hepatitis B drug may offer 'functional cure' for some patients

New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus

The Economic Times

GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies

GSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achieving a functional cure after six months of treatment. This offers a potential finite treatment course, a significant advancement over lifelong antiviral pills for the over 250 million people globally living with…

AAP

Experimental hepatitis B drug might offer 'functional cure' for a subset of patients

New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

FDA fast-tracks promising hepatitis B drug after ‘remarkable’ trial results

New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus

The Conversation

Wise leadership pays off. Here’s how to apply it in the workplace

In a global context marked by chaos and turbulence, technological advancements, health crises, marketplace alterations, shifting demographics and organizational foolishness, the demand for more adaptive and reflective forms of leadership has become a necessity. Given this context, wisdom can provide a meaningful understanding of “good” leadership to navigate such turbulence…

Barchart

Buying CBRS Stock After the Cerebras IPO Is a Bet on Engineering Magic. That Same Magic Could Be the Kiss of Death.

The Cerebras IPO is the most significant debut in the semiconductor industry since Arm.

MarketBeat

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.

Evening Standard

FTSE 100 closes lower as drugs firms GSK and AstraZeneca struggle

The Guardian - UK

AstraZeneca makes surprise U-turn with £300m pharma investment in UK

Drugmaker had stalled large-scale projects in England but has now pledged investment at two sites, announced by Keir Starmer

Evening Standard

Shot in the arm for GSK and AstraZeneca from cancer drug sales

The blue chip drug makers saw first quarter earnings beat market expectations.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.